These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25271612)

  • 41. Exemestane or tamoxifen?
    Ueda M; Toji E; Noda S
    Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
    [No Abstract]   [Full Text] [Related]  

  • 42. 3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience.
    Caruso M; Castiglione G; Aiello R; Alí M; Chiarenza M; Dimarco R; Fallica G; Di Leo MG; Sanó MV; Taibi E; Zacchia A; Miano E; Caruso F
    Future Oncol; 2015; 11(23):3109-12. PubMed ID: 26544787
    [No Abstract]   [Full Text] [Related]  

  • 43. Reproductive endocrinology: triptorelin ovarian suppression during breast cancer chemotherapy.
    Ginsburg ES; Partridge AH
    Nat Rev Endocrinol; 2011 Sep; 7(11):637-8. PubMed ID: 21931373
    [No Abstract]   [Full Text] [Related]  

  • 44. Potential late effect of gonadotropin-releasing hormone agonists in combination with chemotherapy for early breast cancer.
    Saloustros E; Stratakis CA
    J Clin Oncol; 2012 Sep; 30(26):3311-2. PubMed ID: 22649148
    [No Abstract]   [Full Text] [Related]  

  • 45. Gonadotropin-releasing hormone analogue for premenopausal women with breast cancer.
    Loibl S; Gerber B
    JAMA; 2011 Oct; 306(16):1760; author reply 1760-1. PubMed ID: 22028347
    [No Abstract]   [Full Text] [Related]  

  • 46. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
    Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
    Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer.
    Montagnani A; Gonnelli S; Cadirni A; Caffarelli C; Del Santo K; Pieropan C; Campagna MS; Montomoli M; Petrioli R; Nuti R
    Eur J Intern Med; 2008 Dec; 19(8):592-7. PubMed ID: 19046724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Factors related to adjuvant ovarian function suppression in premenopausal breast cancer patients].
    Liang Y; Chen XS; Wu JY; Huang O; Zong Y; Nie LJ; Fang Q; He JR; Zhu L; Chen WG; Li YF; Shen KW
    Zhonghua Zhong Liu Za Zhi; 2016 May; 38(5):357-62. PubMed ID: 27188608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
    Thompson D; Taylor DC; Montoya EL; Winer EP; Jones SE; Weinstein MC
    Value Health; 2007; 10(5):367-76. PubMed ID: 17888101
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study.
    Schilder CM; Seynaeve C; Linn SC; Boogerd W; Beex LV; Gundy CM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
    Psychooncology; 2012 May; 21(5):479-87. PubMed ID: 21351188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
    Rossi E; Morabito A; De Maio E; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; Piccirillo MC; D'Aiuto G; D'Aiuto M; Rinaldo M; Botti G; Gallo C; Perrone F; de Matteis A
    J Clin Oncol; 2008 Jan; 26(2):264-70. PubMed ID: 18086795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Hutchinson L
    Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
    [No Abstract]   [Full Text] [Related]  

  • 54. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
    van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
    Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjuvant endocrine therapy in premenopausal women with breast cancer.
    Kadakia KC; Henry NL
    Clin Adv Hematol Oncol; 2015 Oct; 13(10):663-72. PubMed ID: 27058571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant treatment of breast cancer with exemestane.
    Tanvetyanon T
    N Engl J Med; 2004 Jul; 351(1):100-2; author reply 100-2. PubMed ID: 15237463
    [No Abstract]   [Full Text] [Related]  

  • 57. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
    Regan MM; Francis PA; Pagani O; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Price KN; Coates AS; Goldhirsch A; Gelber RD
    J Clin Oncol; 2016 Jul; 34(19):2221-31. PubMed ID: 27044936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
    Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
    Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exemestane is effective for the chemoprevention of breast cancer.
    Barton MK
    CA Cancer J Clin; 2011; 61(6):363-4. PubMed ID: 21898372
    [No Abstract]   [Full Text] [Related]  

  • 60. To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
    Iddon J; Bundred NJ
    Expert Rev Anticancer Ther; 2008 Jan; 8(1):9-13. PubMed ID: 18095878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.